Daplusiran

DB19331InvestigationalNucleic Acid Based Therapies

Daplusiran is under investigation in clinical trial NCT06537414 (A Study of Sequential Therapy With Daplusiran/tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)).

Also known as
RNA, (AM-SP-(2'-DEOXY-2'-FLUORO)G-SP-AM-SP-(2'-DEOXY-2'-FLUORO)A-AM-(2'-DEOXY-2'-FLUORO)A-UM-(2'-DEOXY-2'-FLUORO)U-GM-(2'-DEOXY-2'-FLUORO)A-GM-(2'-DEOXY-2'-FLUORO)A-GM-(2'-DEOXY-2'-FLUORO)A-AM-(2'-DEOXY-2'-FLUORO)G-UM-(2'-DEOXY-2'-FLUORO)C-CM-AM-SP-CM),

Resolves to

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of Daplusiran, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.

Create Account